Search
Ketanserin
go.drugbank.com/drugs/DB12465InvestigationalKetanserin has been investigated for the treatment of Septic Shock, Severe Sepsis, and Diabetic Foot Ulcer.
Mixtures: SUFREXAL PClascoterone
go.drugbank.com/drugs/DB12499ApprovedInvestigationalClascoterone (cortexolone 17α-propionate, CB-03-01) is a novel antagonist of androgen receptors. It binds to androgen receptors with high affinity. By competing with androgens for binding to androgen receptors, clascoterone works by bloc...
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2B6 InhibitorsFedratinib
go.drugbank.com/drugs/DB12500ApprovedInvestigationalFedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis. It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval o...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsOmaveloxolone
go.drugbank.com/drugs/DB12513ApprovedInvestigationalOmaveloxolone (RTA-408) is a semisynthetic oleanane triterpenoid with antioxidant and anti-inflammatory properties. Omaveloxolone acts as an activator of nuclear factor (erythroid-derived 2)-like 2 (Nrf2), a transcription factor that mit...
Categories: Cytochrome P-450 CYP2C8 Inducers, Cytochrome P-450 SubstratesLobucavir
go.drugbank.com/drugs/DB12531InvestigationalLobucavir has been used in trials studying the treatment of HIV Infections and Cytomegalovirus Infections.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesSAR-405838
go.drugbank.com/drugs/DB12541InvestigationalSAR405838 has been used in trials studying the treatment of Neoplasm Malignant.
Categories: P-glycoprotein substratesTradipitant
go.drugbank.com/drugs/DB12580ApprovedInvestigationalTradipitant is a selective, high-affinity antagonist at human substance P/neurokinin-1 (NK-1) receptors.
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A InducersEtripamil
go.drugbank.com/drugs/DB12605ApprovedInvestigationalEtripamil is a nondihydropyridine, L-type calcium channel blocker. It is a fast-acting drug with a short duration of action. The nasal formulation of etripamil was first approved by the FDA on December 12, 2025 for the conversion of acut...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesBucindolol
go.drugbank.com/drugs/DB12752InvestigationalBucindolol has been investigated in Heart Failure.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesZoliflodacin
go.drugbank.com/drugs/DB12817ApprovedInvestigationalGonorrhea, caused by Neisseria gonorrhoeae, presents a significant public health challenge due to increasing antimicrobial resistance. Zoliflodacin is a first-in-class spiropyrimidinetrione antibiotic designed to address this need by inh...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates